Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.
Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.
Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.
Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.
For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.
Personalis, Inc. (PSNL) reported Q2 2022 results, with revenues of $18.2 million, down from $21.7 million in Q2 2021. Revenue from biopharma customers rose by 74% to $14.2 million, boosted by $6.8 million from Natera. VA MVP revenues fell sharply to $4.0 million from $13.5 million year-over-year. The company incurred a net loss of $27.5 million and anticipates total 2022 revenues between $62.0 million to $67.0 million. Notably, cash reserves were strong at $233.5 million as of June 30, 2022.
Personalis, Inc. (Nasdaq: PSNL) has filed a lawsuit against Foresight Diagnostics Inc. for infringing its U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394, central to its tumor-informed molecular residual disease (MRD) testing innovations. This legal action seeks both injunctive relief and monetary damages. Personalis emphasizes its long-standing expertise in whole genome sequencing, asserting that its NeXT Personal MRD solution represents a significant advancement in cancer detection, achieving unmatched sensitivity in identifying residual cancer cells.
Personalis, Inc. (NASDAQ: PSNL) will release its second quarter 2022 financial results on August 3, 2022. The company will also host a conference call and webcast at 2:00 p.m. PT to discuss financial outcomes and recent developments. Interested participants can register for the call via the provided link and access the live webinar on the company's website. Personalis is recognized for its advancements in cancer genomics, playing a pivotal role in precision oncology through the Personalis NeXT Platform®.
Personalis, Inc. (NASDAQ: PSNL) has added a new patent to its molecular residual disease (MRD) IP portfolio, issued on January 2013, focusing on tumor detection through whole genome sequencing. The newly granted US Patent No. 11,384,394 enhances the NeXT Personal™ platform, allowing for highly sensitive measurement of tumor burden. This patent strengthens Personalis' position in advanced genomic analysis with 21 issued patents and over 30 pending applications related to cancer detection and genomic sequencing. The approach could lead to earlier detection of cancer recurrence and improved treatment options.
Personalis, Inc. (Nasdaq: PSNL) reported Q1 2022 financial results with revenue of $15.2 million, down from $20.9 million in Q1 2021. Revenue from biopharma customers increased by 53% to $11.7 million, including $4.1 million from Natera. Revenue from the VA MVP dropped to $3.5 million from $13.2 million in the prior year. The company expects full-year 2022 revenue between $62.0 million and $67.0 million, with a projected net loss of $110.0 million to $115.0 million.
Personalis, Inc. (Nasdaq: PSNL) announced its participation in upcoming investor conferences to showcase its advancements in cancer genomics. The company will present at the Bank of America 2022 Healthcare Conference on May 11, 2022, at 6:20 p.m. ET in Las Vegas, and at the UBS Global Healthcare Conference on May 24, 2022, at 3:30 p.m. ET in New York. Personalis is committed to enhancing precision cancer therapies through its innovative NeXT Platform, which evaluates nearly 20,000 human genes from a single sample.
Evaxion Biotech and Personalis announced a collaboration utilizing the ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy of Evaxion's cancer immunotherapy EVX-01. The trial will study the combination of EVX-01 with KEYTRUDA in metastatic melanoma patients. Evaxion's AI tool PIONEER is expected to enhance treatment precision by targeting significant cancer mutations. The partnership aims to improve patient outcomes and advance companion diagnostics. Both companies leverage advanced AI and genomic technologies to boost cancer therapy development.
Personalis, Inc. (Nasdaq: PSNL) announced the appointment of James Azzaro as the Vice President of Diagnostic Sales, a new role aimed at enhancing the company's clinical market presence. With over 20 years in oncology diagnostics, Azzaro is set to lead efforts to grow clinical test volumes and secure reimbursement for the NeXT Dx™ and NeXT Personal™ tests. CEO John West expressed confidence in Azzaro's ability to drive commercial success in partnering with healthcare systems and oncologists across the United States.
Personalis, Inc. (NASDAQ: PSNL) will release its Q1 2022 financial results on May 4, 2022, at 2:00 p.m. PT. Following the release, a conference call will occur to discuss financial results and highlights. Interested participants can join via phone or through a live webcast on the company's website.
Personalis specializes in advanced genomics for cancer treatments, utilizing the Personalis NeXT Platform to provide comprehensive genetic insights from single samples, enhancing precision cancer therapies.
Personalis, Inc. (NASDAQ: PSNL) has published a study in Nature Communications detailing the development of DASH, a machine learning-based algorithm for detecting human leukocyte antigen loss of heterozygosity (HLA LOH). This biomarker is crucial for cancer immunotherapy and helps cancer cells evade immune detection. The study showed DASH's increased sensitivity in identifying HLA LOH across various tumor types among 610 patients, with notable prevalence in non-small cell lung cancer (24%), cervical cancer (38%), and head and neck cancers (40%).
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
What does Personalis, Inc. specialize in?
What are Personalis' main products?
Who can benefit from Personalis' services?
What technologies does Personalis use?
What is the mission of Personalis, Inc.?
How does Personalis support cancer research?
What recent achievements has Personalis made?
What sets Personalis apart from other genomic companies?
Why is genome sequencing important in medical research?
How can I stay updated on Personalis' latest news?
